These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 38445082)

  • 1. Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma.
    Cassanello G; Luna de Abia A; Falchi L
    Oncoimmunology; 2024; 13(1):2321648. PubMed ID: 38445082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma.
    Doraiswamy A; Shah MR; Bannerji R
    Curr Hematol Malig Rep; 2021 Feb; 16(1):72-81. PubMed ID: 33619641
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era.
    González Barca E
    Front Immunol; 2022; 13():909008. PubMed ID: 35928819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
    Trabolsi A; Arumov A; Schatz JH
    Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The value of bispecific antibodies in relapsed and refractory DLBCL.
    Lewis KL; Cheah CY
    Leuk Lymphoma; 2024 Jun; 65(6):720-735. PubMed ID: 38454535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment.
    Bock AM; Nowakowski GS; Wang Y
    Curr Treat Options Oncol; 2022 Feb; 23(2):155-170. PubMed ID: 35182296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An evaluation of glofitamab, the first fixed-duration bispecific antibody for relapsed or refractory large B-cell lymphomas.
    Polgarova K; Trneny M
    Expert Opin Biol Ther; 2024; 24(1-2):7-13. PubMed ID: 38305755
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual target dilemma: navigating epcoritamab vs. glofitamab in relapsed refractory diffuse large B-cell lymphoma.
    Davis JA; Granger K; Sakowski A; Goodwin S; Herbst A; Smith D; Hendrickson L; Nachar VR
    Expert Rev Hematol; 2023; 16(12):915-918. PubMed ID: 37982732
    [No Abstract]   [Full Text] [Related]  

  • 9. Bispecific antibodies in the treatment of relapsed/refractory large B-cell lymphoma.
    Ahmed G; Furqan F; Nasrollahi E; Hamadani M
    Expert Rev Anticancer Ther; 2024 Aug; 24(8):705-715. PubMed ID: 38809821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epcoritamab: First Approval.
    Frampton JE
    Drugs; 2023 Sep; 83(14):1331-1340. PubMed ID: 37597091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on bi-specific monoclonal antibodies for blood cancers.
    Shouse G
    Curr Opin Oncol; 2023 Sep; 35(5):441-445. PubMed ID: 37551951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
    Yamaguchi M
    Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving therapy of DLBCL: Bispecific antibodies.
    Hutchings M
    Hematol Oncol; 2023 Jun; 41(S1):107-111. PubMed ID: 37294965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glofitamab: First Approval.
    Shirley M
    Drugs; 2023 Jul; 83(10):935-941. PubMed ID: 37285013
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel strategies for relapsed/refractory DLBCL; navigating the immunotherapy era in aggressive lymphoma.
    Gordon MJ; Sureda A; Westin JR
    Leuk Lymphoma; 2022 Sep; 63(9):2041-2051. PubMed ID: 35549635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment strategies for patients with diffuse large B-cell lymphoma.
    Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
    Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial.
    Hutchings M; Morschhauser F; Iacoboni G; Carlo-Stella C; Offner FC; Sureda A; Salles G; Martínez-Lopez J; Crump M; Thomas DN; Morcos PN; Ferlini C; Bröske AE; Belousov A; Bacac M; Dimier N; Carlile DJ; Lundberg L; Perez-Callejo D; Umaña P; Moore T; Weisser M; Dickinson MJ
    J Clin Oncol; 2021 Jun; 39(18):1959-1970. PubMed ID: 33739857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific antibodies targeting CD20xCD3 in immunotherapy for adult B-cell lymphoma: insights from the 65th American Society of Hematology 2023 annual meeting.
    Sun H; Xing H; Han L; Song Y; Jiang Z; Liu Y; Yu J
    Expert Opin Biol Ther; 2024 May; 24(5):321-326. PubMed ID: 38717336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges and Opportunities in the Management of Diffuse Large B-Cell Lymphoma in Older Patients.
    Di M; Huntington SF; Olszewski AJ
    Oncologist; 2021 Feb; 26(2):120-132. PubMed ID: 33230948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.